JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 11, 2006; DOI: 10.1124/jpet.106.102103


0022-3565/06/3181-336-344$20.00
JPET 318:336-344, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.102103v1
318/1/336    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Angelone, T.
Right arrow Articles by Tota, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Angelone, T.
Right arrow Articles by Tota, B.

CARDIOVASCULAR

The Emerging Cardioinhibitory Role of the Hippocampal Cholinergic Neurostimulating Peptide

Tommaso Angelone, Yannick Goumon, Maria Carmela Cerra, Marie-Hélène Metz-Boutigue, Dominique Aunis, and Bruno Tota

Departments of Pharmaco-Biology (T.A., M.C.C.) and Cell Biology (T.A., M.C.C., B.T.), University of Calabria, Arcavacata di Rende, Italy; and Institut National de la Santé et de la Recherche Médicale U575 Physiopatologie du Système Nerveux, Strasbourg, France (Y.G., M.-H.M.-B., D.A., T.A.)

Hippocampal cholinergic neurostimulating peptide (HCNP), which derives from phosphatidylethanolamine-binding protein (also named Raf kinase inhibitor protein), enhances acetylcholine synthesis in the hippocampal medial septal nuclei. It is present in the chromaffin secretory granules of the adrenal cells and under stress is cosecreted with peptide hormones and catecholamines. Using the isolated rat heart perfused according to Langendorff to reveal the cardiotropic action of HCNP on the mammalian heart, we showed that rat HCNP exerts, at concentrations of 5 x 10-13 to 10-6 M, a negative inotropism under basal conditions (left ventricular pressure variations ranging from -8.34 ± 0.94% to -21 ± 3.5%) and enhances the cholinergic-mediated negative inotropy through direct interaction with G-protein-coupled muscarinic receptor pathway. Under adrenergic stimulation (isoproterenol), the peptide exerts an antiadrenergic action. The analysis of the percentage of rate pressure product variations in terms of EC50 values of isoproterenol alone (-8.5 ± 0.3; r2 = 0.90) and in the presence of rat HCNP at 0.01 nM (-6.9 ± 0.36; r2 = 0.88) revealed a competitive type of antagonism of the peptide. HCNP does not affect either heart rate or coronary pressure. The evidence that HCNP in mammals may play a novel role as an inhibitory cardiac modulator throughout an involvement of the myocardial G-protein-coupled receptor pathway provides new insights regarding the neurohumoral control of heart function under normal and physiopathological conditions.


Received January 31, 2006; accepted April 6, 2006.

Address correspondence to: Dr. Bruno Tota, Department of Cell Biology, University of Calabria, 87030 Arcavacata di Rende (CS), Italy. E-mail: tota{at}unical.it




This article has been cited by other articles:


Home page
FASEB J.Home page
M. C. Cerra, M. P. Gallo, T. Angelone, A. M. Quintieri, E. Pulera, E. Filice, B. Guerold, P. Shooshtarizadeh, R. Levi, R. Ramella, et al.
The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide
FASEB J, November 1, 2008; 22(11): 3992 - 4004.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.